Health-Related Quality of Life During and After Intraperitoneal Versus Intravenous Chemotherapy for Optimally Debulked Ovarian Cancer: A Gynecologic Oncology Group Study

2008 ◽  
Vol 2008 ◽  
pp. 60-61
Author(s):  
J.T. Thigpen
Keyword(s):  
Quality Of Life ◽  
Gynecologic Oncology ◽  
Gynecologic Oncology Group ◽  
Health Related Quality ◽  
Oncology Group ◽  
Intravenous Chemotherapy ◽  
Oncology Group Study ◽  
Related Quality ◽  
Health Related

Health-Related Quality of Life During and After Intraperitoneal Versus Intravenous Chemotherapy for Optimally Debulked Ovarian Cancer: A Gynecologic Oncology Group Study

2007 ◽  
Vol 25 (4) ◽  
pp. 437-443 ◽  
Author(s):  
Lari B. Wenzel ◽  
Helen Q. Huang ◽  
Deborah K. Armstrong ◽  
Joan L. Walker ◽  
David Cella
Keyword(s):  
Quality Of Life ◽  
Ovarian Cancer ◽  
Patient Reported Outcomes ◽  
Gynecologic Oncology ◽  
Gynecologic Oncology Group ◽  
Health Related Quality ◽  
Patient Reported ◽  
Related Quality ◽  
Health Related

Purpose A Gynecologic Oncology Group (GOG) randomized phase III trial (GOG 172) in optimal stage III epithelial ovarian cancer showed that intravenous (IV) paclitaxel plus intraperitoneal (IP) cisplatin and paclitaxel significantly lengthened progression-free survival and overall survival compared with IV paclitaxel and cisplatin. The purpose of this report is to comprehensively evaluate the patient-reported outcomes associated with IP versus IV therapy. Patients and Methods Four hundred fifteen eligible women were enrolled onto GOG 172 at member institutions. The Functional Assessment of Cancer Therapy–Trial Outcome Index (FACT-TOI; which includes physical, functional, and ovarian subscales) and neurotoxicity (Ntx) and abdominal discomfort (AD) subscales were used to assess patient-reported outcomes. Assessments were completed before random assignment, before cycle 4, and 3 to 6 weeks and 12 months after treatment. Results Physical and functional well-being and ovarian cancer symptoms were significantly worse in the IP arm before cycle 4 (P < .001) and 3 to 6 weeks after treatment (P = .001 for FACT-TOI). Patients in the IP arm also reported significantly worse AD before cycle 4 (P < .001) and significantly worse Ntx 3 to 6 weeks (P = .001) and 12 months (P = .003) after completing IP treatment. In general, however, the quality of life of both groups improved over time. Conclusion During active treatment, patients on the IP arm experienced more health-related quality-of-life disruption, AD, and Ntx compared with patients receiving conventional IV therapy. However, only Ntx remained significantly greater for IP patients 12 months after treatment. This trade-off should be included when discussing treatment options with patients. Future studies to mitigate the added burden associated with IP therapy are planned.

Assessing Health-Related Quality of Life in Gynecologic Oncology

2010 ◽  
Vol 20 (4) ◽  
pp. 664-684 ◽  
Author(s):  
Tim Luckett ◽  
Madeleine King ◽  
Phyllis Butow ◽  
Michael Friedlander ◽  
Tim Paris
Keyword(s):  
Quality Of Life ◽  
Gynecologic Oncology ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related

Quality of life and survival in advanced cervical cancer: A Gynecologic Oncology Group study

2012 ◽  
Vol 125 (2) ◽  
pp. 315-319 ◽  
Author(s):  
Dana M. Chase ◽  
Helen Q. Huang ◽  
Lari Wenzel ◽  
David Cella ◽  
Richard McQuellon ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Cervical Cancer ◽  
Gynecologic Oncology ◽  
Gynecologic Oncology Group ◽  
Advanced Cervical Cancer ◽  
Oncology Group ◽  
Oncology Group Study

Health-Related Quality of Life Results in Pathologic Stage C Prostate Cancer From a Southwest Oncology Group Trial Comparing Radical Prostatectomy Alone With Radical Prostatectomy Plus Radiation Therapy

2008 ◽  
Vol 26 (1) ◽  
pp. 112-120 ◽  
Author(s):  
Carol M. Moinpour ◽  
Katherine A. Hayden ◽  
Joseph M. Unger ◽  
Ian M. Thompson ◽  
Mary W. Redman ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Radical Prostatectomy ◽  
Bowel Function ◽  
Health Related Quality ◽  
Oncology Group ◽  
Southwest Oncology Group ◽  
Related Quality ◽  
Health Related

Purpose To compare short- and long-term effects of adjuvant treatment versus observation after surgery on health-related quality of life (HRQL) of prostate cancer patients. Patients and Methods The Southwest Oncology Group (SWOG) intergroup trial compared radical prostatectomy (RP) plus observation versus RP plus adjuvant radiation therapy (RT). Two-hundred seventeen of 425 therapeutic trial patients were eligible and registered to the HRQL study. Patients completed the SWOG Quality of Life Questionnaire (emotional, physical, social, and role function; general symptom status; treatment/disease-specific symptoms; and global HRQL [GHRQL]) at baseline, 6 weeks, 6 months, and annually for 5 years. Prespecified outcomes were three genitourinary symptoms (bowel function tenderness, frequent urination, and erectile dysfunction [ED]) and measures of physical and emotional function. Adjustments were made for the baseline score. Results Patients receiving adjuvant RT reported worse bowel function (through approximately 2 years) and worse urinary function. There were no statistically significant differences for ED. GHRQL was initially worse for the RP+RT arm but improved over time and was better at the end of the period than the GHRQL reported for RP alone (treatment arm × time interaction, P = .0004). Symptom distress was significantly worse for the RP+RT arm compared with the RP alone arm, but the treatment arms did not differ with respect to other general measures of HRQL. Conclusion The addition of RT to surgery resulted in more frequent urination, as well as early report of more bowel dysfunction, although bowel function differences disappeared over the 5-year period. The addition of RT did not negatively impact ED.

Sign in / Sign up

Export Citation Format

Share Document